Indian pharmaceutical company Zydus Lifesciences (NSE:ZYDUSLIFE) announced on Wednesday that its venture capital arm Zynext Ventures USA LLC has invested in Feldan Therapeutics, a Canadian early clinical-stage pharmaceutical company focused on developing treatments based on intracellular delivery of therapeutics.

Feldan's proprietary Shuttle peptide technology is designed to enable the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes and significantly enhances their quality of life. Additionally, Feldan is advancing a pulmonary programme that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases.

"This partnership with Zynext Ventures marks an exciting step forward in our commitment to improve patients' quality of life and address critical drug delivery challenges," said François-Thomas Michaud, CEO of Feldan Therapeutics. "With Zynext Ventures' strategic expertise and shared dedication to innovation, we are well-positioned to accelerate the development of next-generation therapies."